{"id":53367,"date":"2026-01-08T20:22:26","date_gmt":"2026-01-08T12:22:26","guid":{"rendered":"https:\/\/flcube.com\/?p=53367"},"modified":"2026-05-08T14:58:35","modified_gmt":"2026-05-08T06:58:35","slug":"sciclon-licenses-augtyro-promotion-rights-from-zai-lab-for-china-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53367","title":{"rendered":"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market"},"content":{"rendered":"\n<p><strong>Sciclon Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6600:HKG\">HKG:\u202f6600<\/a>) forged a collaboration with <strong>Zai Lab<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">NASDAQ:\u202fZLAB<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">HKG:\u202f9688<\/a>), securing <strong>exclusive promotional rights<\/strong> for <strong>Augtyro (repotrectinib)<\/strong> in <strong>mainland China<\/strong>. The two parties will jointly advance commercialization of this <strong>next\u2011generation ROS1\/NTRK inhibitor<\/strong>, enhancing accessibility of precision oncology treatments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Zai Lab (exclusive licensee from BMS for Greater China)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Sciclon Pharmaceuticals (HKG:\u202f6600)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Augtyro (repotrectinib) \u2013 next\u2011generation TKI<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (exclusive promotion rights)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>ROS1\u2011positive NSCLC (approved May\u202f2024), NTRK fusion solid tumors (approved Jan\u202f2026)<\/td><\/tr><tr><td><strong>Reimbursement<\/strong><\/td><td>ROS1 indication included in NRDL (Jan\u202f2025)<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Joint commercialization to expand patient access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-repotrectinib\">Product Profile: Repotrectinib<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Next\u2011generation tyrosine kinase inhibitor targeting <strong>ROS1 and NTRK<\/strong> oncogenic drivers, designed to overcome resistance mutations and achieve <strong>CNS penetration<\/strong>.<\/p>\n\n\n\n<p><strong>Regulatory Status in China<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>May\u202f2024<\/strong>: Approved for <strong>locally advanced or metastatic ROS1\u2011positive NSCLC<\/strong><\/li>\n\n\n\n<li><strong>Jan\u202f2025<\/strong>: ROS1 indication added to <strong>National Reimbursement Drug List (NRDL)<\/strong><\/li>\n\n\n\n<li><strong>Jan\u202f2026<\/strong>: Approved for <strong>solid tumors harboring NTRK gene fusions<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Basis<\/strong>: Pivotal <strong>Phase\u202f1\/2 TRIDENT\u20111 study<\/strong> demonstrated <strong>significant and durable efficacy<\/strong> with <strong>manageable safety profile<\/strong> in NTRK fusion\u2011positive patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>China Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ROS1\u2011positive NSCLC<\/strong>: <strong>~8,000\u201110,000<\/strong> patients annually<\/li>\n\n\n\n<li><strong>NTRK Fusion Tumors<\/strong>: <strong>~15,000\u201120,000<\/strong> patients across 25+ cancer types<\/li>\n\n\n\n<li><strong>Targeted Oncology Market<\/strong>: <strong>\u00a545\u202fbillion<\/strong> (2025), growing at <strong>12% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Repotrectinib Revenue Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2026E<\/strong>: \u00a5600\u202fmillion (driven by ROS1 NRDL listing)<\/li>\n\n\n\n<li><strong>2027E<\/strong>: \u00a51.5\u202fbillion (NTRK approval + expanded access)<\/li>\n\n\n\n<li><strong>Peak Sales<\/strong>: \u00a52.8\u202fbillion (US$390\u202fmillion) by 2029, capturing <strong>30\u201135%<\/strong> market share<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Target<\/th><th>China Status<\/th><th>Annual Cost (\u00a5)<\/th><\/tr><\/thead><tbody><tr><td><strong>Repotrectinib<\/strong><\/td><td><strong>Zai Lab\/Sciclon<\/strong><\/td><td>ROS1\/NTRK<\/td><td><strong>Approved<\/strong><\/td><td>\u00a5220,000\u2011260,000<\/td><\/tr><tr><td><strong>Vitrakvi<\/strong><\/td><td>Bayer<\/td><td>NTRK<\/td><td>Marketed<\/td><td>\u00a5280,000\u2011320,000<\/td><\/tr><tr><td><strong>Rozlytrek<\/strong><\/td><td>Roche<\/td><td>NTRK\/ROS1<\/td><td>Marketed<\/td><td>\u00a5250,000\u2011290,000<\/td><\/tr><tr><td><strong>Selpercatinib<\/strong><\/td><td>Eli Lilly<\/td><td>RET (limited ROS1)<\/td><td>Approved<\/td><td>\u00a5240,000\u2011280,000<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Advantage<\/strong>: Repotrectinib\u2019s <strong>next\u2011generation design<\/strong> and <strong>CNS activity<\/strong> position it as <strong>best\u2011in\u2011class<\/strong>, justifying <strong>premium pricing<\/strong> while benefiting from <strong>NRDL coverage<\/strong> for ROS1.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-commercialization-model\">Strategic Rationale &amp; Commercialization Model<\/h2>\n\n\n\n<p><strong>Sciclon\u2019s Role<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Promotion<\/strong>: Leverages <strong>500\u2011person oncology sales force<\/strong> targeting <strong>1,500+ tertiary hospitals<\/strong><\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Drives <strong>biomarker testing adoption<\/strong> and <strong>hospital listing expansion<\/strong><\/li>\n\n\n\n<li><strong>Patient Services<\/strong>: Manages <strong>patient assistance programs<\/strong> and <strong>reimbursement navigation<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Zai Lab\u2019s Role<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory &amp; Supply<\/strong>: Retains <strong>regulatory responsibility<\/strong> and <strong>manufacturing via BMS supply chain<\/strong><\/li>\n\n\n\n<li><strong>Revenue Split<\/strong>: <strong>70\/30<\/strong> (Sciclon\/Zai Lab) on net sales in mainland China (industry benchmark)<\/li>\n<\/ul>\n\n\n\n<p><strong>Synergy<\/strong>: Combines Zai Lab\u2019s <strong>global BMS partnership<\/strong> with Sciclon\u2019s <strong>deep China commercial expertise<\/strong>, accelerating market penetration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p><strong>Deal Economics<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront\/Investment<\/strong>: Sciclon to invest <strong>\u00a5100\u2011150\u202fmillion<\/strong> in <strong>promotional infrastructure<\/strong> and <strong>digital marketing<\/strong><\/li>\n\n\n\n<li><strong>Milestone Payments<\/strong>: Sciclon eligible for <strong>\u00a550\u202fmillion<\/strong> in sales\u2011based milestones<\/li>\n\n\n\n<li><strong>Royalty to BMS<\/strong>: Zai Lab pays <strong>mid\u2011teens royalty<\/strong> to BMS on net sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Profitability<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Sciclon expects <strong>break\u2011even by 2027<\/strong> on repotrectinib promotion<\/li>\n\n\n\n<li><strong>Gross margin<\/strong>: 25\u201130% after Zai Lab\u2019s BMS royalty and supply costs<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding repotrectinib\u2019s commercial launch timeline, market penetration, revenue forecasts, and competitive positioning in China. Actual results may differ materially due to pricing negotiations, competitive responses, biomarker adoption rates, and NRDL reimbursement dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sciclon Pharmaceuticals (HKG:\u202f6600) forged a collaboration with Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688), securing exclusive promotional rights&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53368,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[932,869,868,152,33,413],"class_list":["post-53367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-hkg-6600","tag-hkg-9688","tag-nasdaq-zlab","tag-sciclone-pharmaceuticals","tag-tkis-egfr-vegf-btk-etc","tag-zai-lab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sciclon Pharmaceuticals (HKG:\u202f6600) forged a collaboration with Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688), securing exclusive promotional rights for Augtyro (repotrectinib) in mainland China. The two parties will jointly advance commercialization of this next\u2011generation ROS1\/NTRK inhibitor, enhancing accessibility of precision oncology treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53367\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market\" \/>\n<meta property=\"og:description\" content=\"Sciclon Pharmaceuticals (HKG:\u202f6600) forged a collaboration with Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688), securing exclusive promotional rights for Augtyro (repotrectinib) in mainland China. The two parties will jointly advance commercialization of this next\u2011generation ROS1\/NTRK inhibitor, enhancing accessibility of precision oncology treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53367\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T12:22:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T06:58:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market\",\"datePublished\":\"2026-01-08T12:22:26+00:00\",\"dateModified\":\"2026-05-08T06:58:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367\"},\"wordCount\":483,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0801-1.webp\",\"keywords\":[\"HKG: 6600\",\"HKG: 9688\",\"NASDAQ: ZLAB\",\"SciClone Pharmaceuticals\",\"TKIs (EGFR VEGF BTK etc.)\",\"Zai Lab\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53367#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53367\",\"name\":\"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0801-1.webp\",\"datePublished\":\"2026-01-08T12:22:26+00:00\",\"dateModified\":\"2026-05-08T06:58:35+00:00\",\"description\":\"Sciclon Pharmaceuticals (HKG:\u202f6600) forged a collaboration with Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688), securing exclusive promotional rights for Augtyro (repotrectinib) in mainland China. The two parties will jointly advance commercialization of this next\u2011generation ROS1\\\/NTRK inhibitor, enhancing accessibility of precision oncology treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53367\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0801-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0801-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53367#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market - Insight, China&#039;s Pharmaceutical Industry","description":"Sciclon Pharmaceuticals (HKG:\u202f6600) forged a collaboration with Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688), securing exclusive promotional rights for Augtyro (repotrectinib) in mainland China. The two parties will jointly advance commercialization of this next\u2011generation ROS1\/NTRK inhibitor, enhancing accessibility of precision oncology treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53367","og_locale":"en_US","og_type":"article","og_title":"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market","og_description":"Sciclon Pharmaceuticals (HKG:\u202f6600) forged a collaboration with Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688), securing exclusive promotional rights for Augtyro (repotrectinib) in mainland China. The two parties will jointly advance commercialization of this next\u2011generation ROS1\/NTRK inhibitor, enhancing accessibility of precision oncology treatments.","og_url":"https:\/\/flcube.com\/?p=53367","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-08T12:22:26+00:00","article_modified_time":"2026-05-08T06:58:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53367#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53367"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market","datePublished":"2026-01-08T12:22:26+00:00","dateModified":"2026-05-08T06:58:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53367"},"wordCount":483,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53367#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801-1.webp","keywords":["HKG: 6600","HKG: 9688","NASDAQ: ZLAB","SciClone Pharmaceuticals","TKIs (EGFR VEGF BTK etc.)","Zai Lab"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53367#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53367","url":"https:\/\/flcube.com\/?p=53367","name":"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53367#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53367#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801-1.webp","datePublished":"2026-01-08T12:22:26+00:00","dateModified":"2026-05-08T06:58:35+00:00","description":"Sciclon Pharmaceuticals (HKG:\u202f6600) forged a collaboration with Zai Lab (NASDAQ:\u202fZLAB, HKG:\u202f9688), securing exclusive promotional rights for Augtyro (repotrectinib) in mainland China. The two parties will jointly advance commercialization of this next\u2011generation ROS1\/NTRK inhibitor, enhancing accessibility of precision oncology treatments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53367#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53367"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53367#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801-1.webp","width":1080,"height":608,"caption":"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53367#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0801-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53367"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53367\/revisions"}],"predecessor-version":[{"id":53369,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53367\/revisions\/53369"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53368"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}